Antibodies

#Antibodies #Bispecific therapeutics #Drug development #Drug discovery

Approaching bispecific antibody engineering

Dr Michael Fiebig, Chief Scientific Officer, Absolute Antibody offers insight for those starting with a new bispecific antibody project  who may feel a little daunted by the wealth of formats out there. Over the past 10-plus years, there has been a dramatic rise in the exploitation of bispecific antibodies with… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News #Trends & Analysis

#Antibodies #Covid-19 #Drug discovery #Drug therapy #Infographic #Monoclonal antibodies #Research

Study illuminates surfaces of spike most resistant to antibody escape 

Scientists at La Jolla Institute for Immunology (LJI) have published a detailed map of where human antibodies bind to SARS-CoV-2, which was generated by a global collaboration comparing nearly all leading clinical candidates. The new research, published in Science, will guide the development of more effective Covid-19 antibody… Read More

#Covid-19 #News

#Antibodies #Clinical trials #Data #Monoclonal antibodies

AstraZeneca Imfinzi combination effective with non-small cell lung cancer 

Results from the large, randomised COAST Phase II trial showed oleclumab, an anti-CD73 monoclonal antibody, or monalizumab, an anti-NKG2A monoclonal antibody, in combination with Imfinzi (durvalumab) improved progression-free survival (PFS) and objective response rate (ORR) compared to Imfinzi alone in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had… Read More

#News

#Antibodies #Biotherapeutics #Collaboration #Drug discovery

Collaboration to support preclinical drug discovery research 

Fusion Antibodies has entered into a commercial collaboration with Eurofins to provide laboratories worldwide with high-quality, cost-effective and efficient services that work with one another to support biotherapeutic discovery.   Under the agreement, Fusion Antibodies will provide comprehensive pre-clinical antibody development services from discovery, engineering, and critical reagent supply to Eurofins so that… Read More

#Business & Investment #News

#Antibodies #Immunology / Virology & Vaccines #Malaria #Monoclonal antibodies

Monoclonal antibody prevents malaria in NIH trial 

One dose of a new monoclonal antibody discovered and developed at the National Institutes of Health (NIH) safely prevented malaria for up to nine months in people who were exposed to the malaria parasite. The clinical trial is the first to demonstrate that a monoclonal antibody can prevent malaria… Read More

#News #Trending News

#Antibodies #Biology #Genes

Sino Biological listed on the Shenzhen Stock Exchange 

Sino Biological has announced a successful listing on the Shenzhen Stock Exchange subsidiary ChiNext. A total of 17 million shares were issued for a total of ¥4.98 billion (US$770 million) raised during this initial public offering.   Sino Biological says the listing is an important milestone in its strategic plan for growth. It signifies a new starting… Read More

#Business & Investment #News

Business agreement
#Antibodies #Bioproduction #Flow Cytometry #Life sciences #Proteogenomics #Reagents

PerkinElmer to acquire BioLegend

PerkinElmer has entered into an agreement to acquire BioLegend, provider of life science antibodies and reagents, for approximately US$5.25 billion. The transaction will be the largest in PerkinElmer’s history and is expected to close by the end of the 2021 calendar year, subject to regulatory approvals and other customary closing… Read More

#News

#Antibodies #Biopharmaceuticals #Biotherapeutics #Covid-19 #SARS-CoV-2

Helping Indian biotherapeutic companies advance novel therapeutics

Fusion Antibodies and BioTickle, its distributor in India, are providing local biopharmaceutical organisations with access to biopharmaceutical development capabilities. Since the emergence of Covid-19, Fusion Antibodies has contributed resources into developing a panel of unique protein antigens for use in discovery platforms. To date, the proteins have shown positive profiles… Read More

#News

#Antibodies #Complex medicines #Covid-19 #Drug delivery #Drug development #Drug discovery #Drug targets #Life sciences

Financial benefit of complex medicines to UK life sciences

Shaping the UK into an epicentre for complex medicines is a report by the Medicines Discovery Catapult (MDC) in partnership with the CPI, which showcases the potential for the UK in developing complex medicines. The report details the potential medical and economic impact of this field, and how the UK… Read More

#News

#Antibodies #AstraZeneca #Biomedical research #Covid-19 #Immunology / Virology & Vaccines #Pfizer #Vaccines

Covid antibody levels vary according to vaccine type

Two doses of the Oxford-AstraZeneca Covid-19 vaccine induce lower levels of antibodies that are able to recognise and fight the SARS-CoV-2 Delta variant (B.1.617.2) than against other strains. These laboratory findings from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre are published… Read More

#Covid-19 #News #Trending News

#Antibodies #Biotherapeutics #Clinical trial

IONTAS collaboration with F-star enters clinical trial

F-star Therapeutics has dosed the first patients in a Phase I clinical trial, with FS222, a CD137/PD-L1 bispecific antibody. IONTAS applied its proprietary technology to generate a component utilised within FS222, which was subsequently licenced to F-star. António Parada, CEO at IONTAS, commented: “We are delighted with the progress of… Read More

#News

#Antibodies #Biopharmaceutical #Collaboration #Sitting Down With

Antibody engineering: the importance of collaboration and successful partnerships

The latest DDW Sponsored Sitting Down With podcast features Melina Mathur, Product Manager for Biopharma at Twist Bioscience. Mathur talks about Twist’s antibody expertise, drawing on the company’s experience and looking at the importance of collaboration. Listen to hear Mathur discuss the company philosophy, how the pandemic has affected… Read More

#Podcasts

#Antibodies #Biopharmaceutical #Collaboration

Antibody engineering: the importance of collaboration – podcast

The latest DDW Sitting Down With podcast features Melina Mathur, Product Manager for Biopharma at Twist Bioscience. Mathur talks about Twist’s antibody expertise, drawing on the company’s experience and looking at the importance of collaboration. The company has created some successful partnerships and she explains what these look like, why… Read More

#Editor's Choice #News

#Antibodies #Drug development #Life sciences

Picking the right custom antibody provider

Selecting the right custom antibody provider for a project is an important decision. It can mean the difference between a breakthrough or failure. It is therefore important where and how antibodies are made. With this infographic, available for free download, you will learn what sets Fortis Life Science’s Bethyl… Read More

#Editor's Choice #News

#Antibodies #Biotherapeutics #Drug discovery #Drug targets #Genovac

Berkeley Lights: Improving antibody discovery

John Proctor, Senior Vice President of Antibody Therapeutics at Berkeley Lights, and Brian Walters, President/CEO of Genovac Antibody Discovery, talk with DDW’s Megan Thomas about the company’s new Beacon system, which the CRO believes may be the new gold standard in antibody discovery with the potential to up antibody discovery. Read More

#Editor's Choice #Exclusive Content #News